Miguel Chamah-Farre, MD
General Practice · Hialeah, FLNPI 1912914698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Esperion Therapeutics, Inc. at 25.3% of the total. Reporting peaked in 2021 at $2,509 and has fallen 73.5% since, to $665 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $42.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Esperion Therapeutics, Inc.$2K
- Boehringer Ingelheim$1K
- Amgen$1K
- Lilly USA, LLC$487
- Abbott$456
- AbbVie$388
- plus $3K from 24 others
Across 39 payments — averaging $2669.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Esperion Therapeutics, Inc.$49K
- Currax Pharmaceuticals LLC$44K
- Bristol Myers Squibb$11K
What the payments were for
- Food & beverage$8,75599%
- Education$120%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Esperion Therapeutics, Inc. | 23 | $2,237 |
| Boehringer Ingelheim | 39 | $1,232 |
| Amgen(2 entities) | 22 | $1,076 |
| Lilly USA, LLC | 18 | $487 |
| Abbott | 5 | $456 |
| AbbVie(2 entities) | 8 | $388 |
| Amarin Pharma, Inc. | 11 | $375 |
| Novartis | 8 | $315 |
| Radius Health, Inc. | 8 | $301 |
| Novo Nordisk | 4 | $270 |
| AstraZeneca | 12 | $187 |
| Mannkind Corporation | 2 | $166 |
| Edwards Lifesciences | 2 | $156 |
| Davol Inc. | 1 | $147 |
| Johnson & Johnson | 7 | $126 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $113 |
| Merck | 6 | $113 |
| Kowa Pharmaceuticals America, Inc. | 6 | $111 |
| Zyla Life Sciences, Inc. | 7 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $70 |
| Exact Sciences | 3 | $67 |
| Astellas Pharma US Inc | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Genentech USA, Inc. | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Dexcom, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXLIZET$2,137
- NEXLETOL$2,137
- Repatha$641
- JARDIANCE$614
- Vascepa$230
- RYBELSUS$230
- ENTRESTO$228
- ARISTA AH FLEXITIP$147
- Mitra Clip system$129
- Edwards SAPIEN 3 Transcatheter Heart Valve$125
- PRALUENT$125
- Prolia$125
- Creon$120
- ZEPBOUND$114
- NURTEC ODT$113
- Tymlos$108
- AFREZZA$107
- UBRELVY$104
How this compares
$8,827 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 50 | $57,446 |
| EliquisApixaban | 17 | $23,541 |
| ProliaDenosumab | 12 | $20,402 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $17,114 |
| MounjaroTirzepatide | 15 | $15,392 |
| EntrestoSacubitril/Valsartan | 11 | $11,060 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 62 | $8,790 |
| LinzessLinaclotide | 12 | $6,410 |
| SynthroidLevothyroxine Sodium | 43 | $5,549 |
| Novolog FlexpenInsulin Aspart | 11 | $3,825 |
| Atorvastatin Calcium | 569 | $3,578 |
| DexilantDexlansoprazole | 11 | $3,335 |
| Tadalafil | 13 | $2,622 |
| Levothyroxine Sodium | 171 | $2,460 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 26 | $2,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $270 | $57,44650 claims |
| PfizerEliquis | $15 | $23,54117 claims |
| AmgenProlia | $1,076 | $20,40212 claims |
| Boehringer IngelheimCombivent Respimat | $1,232 | $17,11414 claims |
| Lilly USA, LLCMounjaro | $487 | $15,39215 claims |
| AbbVieLinzess, Synthroid | $388 | $11,95955 claims |
| NovartisEntresto | $315 | $11,06011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Hialeah
- Daniel BasultoHialeah$31K
- Jose GonzalezHialeah$21K
- Julian MarquezHialeah$18K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.